Ann: Rhythm Maintains Ongoing ISO13485 Certification, page-33

I think you are dreaming that they will commercialise this year. It's the usual carrot for the retail investor.

You may want to also look at GRAIL's Galleri product. Yes it's about $1,000 a blood test but do you you really believe that Rhythm is going to sell its kit for $30-$40?

Many companies in the US and Europe and even Australia have first mover advantage. Ryththm doesn't have this regardless of what they say it costs to produce. I doubt they have factored in operating costs notwithstanding marketing costs. That in itself would be tens of millions of dollars and lots more.

Did anyone here look at ACL? They have "Aspect Liquid Biopsy". You can do the further research yourself.

There is nothing innovative about Rhythm's COLOSTAT. John Hopkins scientists, the Mayo Clinic have been onto liquid biopsies for over a decade and more.

ACL is capped at just $970m and I they made around $128 million (as per recent announcement) in NPAT for the six months ended 31 Dec 2021. Actual results being released on Thursday.

Rhythm market cap circa $250m. No sales,skeleton staff, looking for senior scientist (on their website).

I just scratch my head.

GLTA.